Skip to content
value.today
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc.

Total raised
$66 M
1 round on record
Latest round
$66 M
Jun 2018
First round on record
Jun 2018
Today
Went public
See the company page

Vir Biotechnology, Inc. is listed today as Vir Biotechnology, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Vir Biotechnology, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2020$32 MPrivate placement after listing$10 to $50 million

Vir Biotechnology, Inc.: Private sale, May 2020

Investors in this round

1 investor had bought by the notice of May 8, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Vir Biotechnology, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$32 M of $32 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • George Scangos · Executive Officer, Director
  • Herbert Virgin · Executive Officer
  • Howard Horn · Executive Officer
  • Jay Parrish · Executive Officer
  • Kristina Burow · Executive Officer
  • Michael Kamarck · Executive Officer
  • Phillip Pang · Executive Officer
  • Dipchand Nishar · Director
  • Phillip Sharp · Director
  • Robert More · Director
  • Robert Nelsen · Director
  • Robert Perez · Director
  • Saira Ramasastry · Director
  • Vicki Sato · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Howard Horn, Cfo. Source: SEC Form D, newest notice filed May 8, 2020. Read the notice at the SEC.

equitySEC
Apr 2020$250 MPrivate placement after listing$250 million to $1 billion

Vir Biotechnology, Inc.: Private sale, Apr 2020

Investors in this round

1 investor had bought by the notice of May 8, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Vir Biotechnology, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$250 M of $250 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • George Scangos · Executive Officer, Director
  • Herbert Virgin · Executive Officer
  • Howard Horn · Executive Officer
  • Jay Parrish · Executive Officer
  • Kristina Burow · Executive Officer
  • Michael Kamarck · Executive Officer
  • Phillip Pang · Executive Officer
  • Dipchand Nishar · Director
  • Phillip Sharp · Director
  • Robert More · Director
  • Robert Nelsen · Director
  • Robert Perez · Director
  • Saira Ramasastry · Director
  • Vicki Sato · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Howard Horn, Cfo. Source: SEC Form D, newest notice filed May 8, 2020. Read the notice at the SEC.

equitySEC
Jun 2018$66 MNo. 1$50 to $250 million

Vir Biotechnology, Inc.: Raise no. 1, Jun 2018

Investors in this round

5 investors had bought by the notice of Jun 29, 2018: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Vir Biotechnology, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$66 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alex Bangs · Executive Officer
  • Alpna Seth · Executive Officer
  • George Scangos · Executive Officer, Director
  • Herbert Virgin · Executive Officer
  • Howard Horn · Executive Officer
  • Jay Parrish · Executive Officer
  • Michael Kamarck · Executive Officer
  • Dipchand Nishar · Director
  • Klaus Frueh · Director
  • Kristina Burow · Director
  • Philip Sharp · Director
  • Robert More · Director
  • Robert Nelsen · Director
  • Robert Perez · Director
  • Thomas Daniel · Director
  • Vicki Sato · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Howard Horn, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 29, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Vir Biotechnology, Inc., its revenue in fiscal 2025 came from these product and service lines: License and collaboration revenue $63.13 million (92%), Other revenue $3.39 million (5%), Grant revenue $2.04 million (3%).

    Annual report (SEC XBRL) · Dec 2025

  • Vir Biotechnology, Inc. chose not to state its revenue in its newest notice of a funding round (May 2020).

    SEC Form D · May 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2020

Products and services#

No products or services of Vir Biotechnology, Inc. are on record.

Investors#

20 named in official filings. Open an investor to see everything it has backed.

Investors in Vir Biotechnology, Inc.
InvestorKindAmountRoundRoleSource
Abu Dhabi Investment AuthorityFund or asset managernot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Alaska Permanent Fund CorpFund or asset managernot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
ARCH Venture Fund IX, L.P.Venture capitalnot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
ARCH Venture Fund IX Overage, L.P.Venture capitalnot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
ARCH Venture Partners IX, LLCVenture capitalnot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
ARCH Venture Partners IX, L.P.Venture capitalnot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
ARCH Venture Partners IX Overage, L.P.Venture capitalnot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Bill & Melinda Gates FoundationOthernot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Fullerton Management Pte LtdFund or asset managernot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Philip A. SharpPersonnot statednot statedHeld Series A-1 preferred stock, director (Form 3, 2019)SEC Form 3
Platinum Falcon B 2018 RSC LtdCompanynot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Platinum International Investment Holding RSC LtdFund or asset managernot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Q-Ventures Program II (Co-Invest Holdings) Ltd.Venture capitalnot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Robert J. MorePersonnot statednot statedHeld Series A-2 preferred stock, director (Form 3, 2019)SEC Form 3
SB Investment Advisers (UK) LTDFund or asset managernot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Softbank Vision Fund (aiv M1) L.P.Fund or asset managernot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
SVF Endurance (Cayman) LtdCompanynot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Temasek Holdings (Private) LtdFund or asset managernot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Temasek Life Sciences Private LtdCompanynot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
TLS Beta Pte. Ltd.Companynot statednot statedHeld Series A-1 and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 5 investors.

Largest shareholders today

Institutions holding Vir Biotechnology, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vir Biotechnology, Inc.
NameRoleNamed in
George ScangosExecutive officerMay 2020
Herbert VirginExecutive officerMay 2020
Howard HornExecutive officerMay 2020
Jay ParrishExecutive officerMay 2020
Kristina BurowExecutive officerMay 2020
Michael KamarckExecutive officerMay 2020
Phillip PangExecutive officerMay 2020
Alex BangsExecutive officerJun 2018
Alpna SethExecutive officerJun 2018
Dipchand NisharDirectorMay 2020
George ScangosDirectorMay 2020
Phillip SharpDirectorMay 2020
Robert MoreDirectorMay 2020
Robert NelsenDirectorMay 2020
Robert PerezDirectorMay 2020
Saira RamasastryDirectorMay 2020
Vicki SatoDirectorMay 2020
Klaus FruehDirectorJun 2018
Kristina BurowDirectorJun 2018
Philip SharpDirectorJun 2018
Thomas DanielDirectorJun 2018

About

Biotech company.

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.